Company profile: KSQ Therapeutics
1.1 - Company Overview
Company description
- Provider of CRISPR-enabled drug discovery and development, offering KSQ-4279, a USP1 inhibitor in Phase 1 for advanced solid tumors targeting DNA damage repair; eTIL autologous cell therapies (KSQ-001, KSQ-004) engineered for enhanced tumor killing in solid tumors; the CRISPRomics platform for target identification in oncology and autoimmune diseases; CRISPR2 guide-pairing technology; and the ExPRESS process for eTIL manufacturing.
Products and services
- CRISPRomics® Platform: CRISPR-based discovery platform identifying and validating gene targets for oncology and autoimmune diseases, enabling high-confidence drug development
- ETIL® (KSQ-001 and KSQ-004): Autologous cell therapy candidates engineered to enhance tumor-killing abilities in solid tumors utilizing CRISPR gene editing, produced via ExPRESS™ to reduce tumor-to-vein turnaround times
- KSQ-4279: Small-molecule inhibitor of USP1 in Phase 1 trials for advanced solid tumors, targeting DNA damage repair processes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to KSQ Therapeutics
Quanterix
HQ: United States
Website
- Description: Provider of ultrasensitive biomarker detection solutions for healthcare, leveraging Simoa technology to enable earlier disease detection and improved treatment by measuring biomarkers at lower levels. Offerings include Simoa assays across neurology, oncology, cardiology, immunology and infectious disease; the HD-X automated immunoassay analyzer; SP-X and SR-X detection systems; and the CLIA-certified Simoa Accelerator Laboratory.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quanterix company profile →
Smart Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical drug discovery and development focused on orally administered drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Smart Therapeutics company profile →
Genable Technologies
HQ: Ireland
Website
- Description: Provider of gene medicines to treat "dominant" genetic diseases, developed by a privately held, venture backed, Dublin (Ireland) based bio-pharmaceutical company, based on the pioneering work of Professor Jane Farrar, Dr Paul Kenna & Professor Peter Humphries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genable Technologies company profile →
Resolution Bioscience
HQ: United States
Website
- Description: Provider of next-generation liquid biopsy cancer diagnostics using NGS to interrogate cell-free DNA from blood. Offerings include the ctDx Platform; ctDx FIRST, an FDA-approved NGS assay for comprehensive genomic profiling of 109 genes and detection of KRAS G12C in NSCLC; ctDx Lung for real-time NSCLC genotype assessment; custom liquid-biopsy panels for clinical trials and companion diagnostics; and TCR profiling for immuno-oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Resolution Bioscience company profile →
Synlogic
HQ: United States
Website
- Description: Provider of synthetic biotic medicines designed to perform metabolic functions to treat diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synlogic company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for KSQ Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to KSQ Therapeutics
2.2 - Growth funds investing in similar companies to KSQ Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for KSQ Therapeutics
4.2 - Public trading comparable groups for KSQ Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →